Fina Biosolutions LLC is a privately held research and development-stage biotechnology company that discovers, develops, and collaborates to commercialize novel vaccine conjugates for the prevention of life-threatening diseases. FinaBio has patented novel techniques to conjugate, purify, and manufacture conjugates using its proprietary chemistry to create complex conjugate vaccines. The technology is currently licensed by leading vaccine manufacturers in both Europe and Asia, including GlaxoSmithKline for marketed vaccines Synflorix™ Menitorix™, Nimenrix™, The Serum Institute of India, Pvt., Ltd. (SIIPL) vaccine Pneumosil®, The Chengdu Institute of Biological Products Co., Ltd (CDIBP) China, and others. The company markets CRM197 (trade name EcoCRM®), a vaccine carrier protein for both pre-clinical and clinical research programs, and generates revenues through technology licensing milestones, and royalties.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):